Summarizing the month in European dealmaking.
You may also be interested in...
87 of the top 100 German OTC manufacturers are now reporting inflation-driven price increases, up from 72 at the same point last year. Sempora Consulting suggests a number of strategies to address the current economic challenges companies face.
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?